Pulse Biosciences reported its first‑quarter 2026 financial results, posting a GAAP net loss of $18.6 million and an earnings per share of –$0.27. The loss per share beat the consensus estimate of –$0.32, a surprise of $0.05 or 15.6 %. The beat was driven by tighter operating costs relative to the prior quarter, even as the company continued to invest heavily in clinical development.
Revenue for the quarter was $0.401 million, a figure that fell short of the consensus estimate of $0.40 million (about $250 k). The miss was largely due to the company’s modest sales of its soft‑tissue ablation product, nPulse Vybrance, which generated $0.401 million in capital and disposable revenue. The company had no sales from its electrophysiology segment in this period, which explains the flat top‑line compared with the $0.264 million reported in Q4 2025.
The company’s cash position stood at $68.3 million as of March 31 2026, down from $119.3 million a year earlier. The decline reflects ongoing cash burn driven by increased spending on clinical trials for the nPulse Cardiac Catheter System and other electrophysiology programs. Management emphasized that the investment is intended to accelerate regulatory approvals and market entry.
Pulse Biosciences’ guidance for the full year remains unchanged. The company reiterated its outlook for 2026 revenue of $0.4 million and a GAAP net loss of $18.6 million, underscoring its focus on maintaining cash runway while pursuing clinical milestones.
Analysts noted that while the EPS beat suggests improved cost discipline, the revenue miss and continued cash burn signal that the company is still in a heavy‑investment phase. The market reaction on the day of the release was muted, reflecting uncertainty about the company’s ability to translate clinical progress into top‑line growth.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.